HH-120

HH-120 is a recombinant fusion protein drug candidate developed for the prevention and treatment of COVID-19. It is designed as an IgM-like ACE2 fusion protein with broad-spectrum neutralizing activity against all ACE2-utilizing coronaviruses, including all known variants of SARS-CoV-2. The drug acts by inhibiting the SARS-CoV-2 spike glycoprotein, thereby blocking viral infection and spread. It is administered via nasal spray or nebulization inhalation, offering localized antiviral action with minimal systemic exposure. Clinical studies have demonstrated that HH-120 accelerates viral clearance in infected subjects and has a favorable safety profile with mostly mild and transient adverse events. The developer is Huahui Health, a Beijing-based biotechnology company focused on virology therapies[1][4][5][7].